Abstract

Quiescence in stem cells is traditionally considered as a state of inactive dormancy or with poised potential. Naive mouse embryonic stem cells (ESCs) can enter quiescence spontaneously or upon inhibition of MYC or fatty acid oxidation, mimicking embryonic diapause in vivo. The molecular underpinning and developmental potential of quiescent ESCs (qESCs) are relatively unexplored. Here we show that qESCs possess an expanded or unrestricted cell fate, capable of generating both embryonic and extraembryonic cell types (e.g., trophoblast stem cells). These cells have a divergent metabolic landscape comparing to the cycling ESCs, with a notable decrease of the one-carbon metabolite S-adenosylmethionine. The metabolic changes are accompanied by a global reduction of H3K27me3, an increase of chromatin accessibility, as well as the de-repression of endogenous retrovirus MERVL and trophoblast master regulators. Depletion of methionine adenosyltransferase Mat2a or deletion of Eed in the polycomb repressive complex 2 results in removal of the developmental constraints towards the extraembryonic lineages. Our findings suggest that quiescent ESCs are not dormant but rather undergo an active transition towards an unrestricted cell fate.

Stem cell quiescence is generally considered as an inactive state with poised potential. Here, Khoa et al. find that quiescent embryonic stem cells actively maintain a dynamic reservoir of cells with unrestricted cell fate that converges on S-adenosylmethionine and H3K27me3 status.

Details

Title
Quiescence enables unrestricted cell fate in naive embryonic stem cells
Author
Khoa, Le Tran Phuc 1   VIAFID ORCID Logo  ; Yang, Wentao 2 ; Shan, Mengrou 3 ; Zhang, Li 3 ; Mao, Fengbiao 4 ; Zhou, Bo 5 ; Li, Qiang 6 ; Malcore, Rebecca 5   VIAFID ORCID Logo  ; Harris, Clair 5 ; Zhao, Lili 7 ; Rao, Rajesh C. 6   VIAFID ORCID Logo  ; Iwase, Shigeki 5   VIAFID ORCID Logo  ; Kalantry, Sundeep 5   VIAFID ORCID Logo  ; Bielas, Stephanie L. 5   VIAFID ORCID Logo  ; Lyssiotis, Costas A. 3 ; Dou, Yali 2   VIAFID ORCID Logo 

 University of Southern California, Department of Medicine, Norris Comprehensive Cancer Center, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Michigan Medical School, Department of Molecular and Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370) 
 University of Southern California, Department of Medicine, Norris Comprehensive Cancer Center, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853) 
 University of Michigan Medical School, Department of Molecular and Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370) 
 Peking University Third Hospital, Institute of Medical Innovation and Research, Beijing, China (GRID:grid.411642.4) (ISNI:0000 0004 0605 3760) 
 University of Michigan Medical School, Department of Human Genetics, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370) 
 University of Michigan, Department of Ophthalmology & Visual Sciences, W.K. Kellogg Eye Center, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347) 
 Beaumont Hospital, Wayne, Wayne, USA (GRID:grid.414575.6) (ISNI:0000 0004 0424 3608) 
Pages
1721
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2931863460
Copyright
© The Author(s) 2024. corrected publication 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.